Benevolent news
London, 3 February 2022, BenevolentAI, a leading clinical-stage AI-drug discovery company, today announced details of an AI research collaboration with the Helix Group, a Stanford University-based research lab led by Professor Russ Altman. The partnership aims to discover more effective methods to extract knowledge from biological and clinical information and ultimately extend the potential of artificial intelligence in helping scientists discover and develop better medi
On Thursday, a panel of WHO experts strongly recommended the janus kinase (JAK) inhibitor baricitinib, a drug owned by Eli Lilly, for patients with severe or critical COVID-19 in combination with corticosteroids.
BenevolentAI first identified baricitinib as a COVID-19 treatment candidate in January 2020 using its artificial intelligence (AI) platform. BenevolentAI was able
Two novel targets identified through the existing collaboration have already been added to AstraZeneca’s portfolio
London, 13 January 2021, BenevolentAI, a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca, doubling the number of disease areas being explored through the partnership. The three-year expansion includes an upfront payment, research funding, development milestone p
London, 07 January, 2022BenevolentAI, a leading clinical-stage AI drug discovery company, today announced that Joanna Shields, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January, 2022 at 8.00am ET / 13.00 GMT.
About BenevolentAI
BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the combined capabi
- Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca
- Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to AstraZeneca’s portfolio in Q1 2021
London, 15 December 2021: BenevolentAI, a leading clinical-stage AI drug discovery company, announce
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population.
- Early in the pandemic, BenevolentAI researchers identified Baricitinib as a potential treatment for COVID-19 and published the hypothesis in Apr. 8, yyyy
BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis.
London, 11 February 2020 - This significant milestone sees a best in class, novel multi-target drug developed using BenevolentAI`s scientific and technical expertise now entering human c
BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter the Company’s portfolio.
- Novel chronic kidney disease (CKD) target from the partnership enters AstraZeneca’s portfolio
- AI-generated target was identified through The Benevolent Platform® and AstraZeneca&rs
Peer-reviewed resultsfrom the Adaptive COVID-19 Treatment Trial (ACTT-2) published in the New England Journal of Medicine showed that baricitinib in combination with remdesivir reduces recovery time, improves clinical status and demonstrates a trend towards a decrease in m